Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Trial readouts
Semaglutide carbon model: what it found
A UK model estimated slightly lower lifetime emissions in two obesity populations but higher emissions with established cardiovascular disease.
Trial readouts
COMBINE 4: IcoSema vs insulin glargine
COMBINE 4 put once-weekly IcoSema against daily insulin glargine U100 in type 2 diabetes. HbA1c fell further, and bodyweight moved the other way.
Trial readouts
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
Trial readouts
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.